Transformed two major R&D organizations, enabling expeditious development and subsequent approval of groundbreaking therapies like Denosumab and Keytruda
M.D., Ph.D., President, Merck Research Laboratories
Roger M. Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories was formerly executive vice president and head of R&D at Amgen for twelve years. His work has enabled an unparalleled number of breakthrough small molecule and biologic medicines including Denosumab and the anti-PD-1 therapy, Keytruda. Dr. Perlmutter’s laser focus on grievous illnesses and his skillful direction led to Keytruda receiving accelerated approval status globally. Early in his career, Dr. Perlmutter was a professor at the University of Washington and chairman of the Department of Immunology. As a Howard Hughes Medical Institute investigator, he focused on understanding the signaling pathways that control lymphocyte activation. Dr. Perlmutter received his M.D. and Ph.D. degrees from Washington University, St. Louis and completed clinical training at Massachusetts General Hospital and University of California, San Francisco. He is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science.